Information  X 
Enter a valid email address

ValiRx cancer treatment JV progressing well

By BFN News | 08:33 AM | Thursday 28 September, 2017

ValiRx, the clinical stage biotechnology company, said its joint venture with Tangent Reprofiling is progressing well. ValiSeek was formed to progress the novel cancer treatment drug, VAL401, into clinical efficacy trials for the treatment of lung cancer and other oncology indications. First dosing in the Phase II clinical trial commenced in October 2016. Since the trial in Tbilisi, Georgia closed to new patients in June, the company have since collated, verified and analysed the data collected over the first two weeks of all patients. The results include the pharmacokinetic measurements recorded for each patient after a single 2 mg dose of VAL401. This is carried out by a blood measurement of the active pharmaceutical ingredient in VAL401, Risperidone, and the blood measurements of the known by-product, or metabolite, of Risperidone, 9-hydroxy-Risperidone. The analysis revealed some significant differences between the absorption and subsequent metabolism of the conventionally formulated Risperidone. It demonstrated that this patient population biologically interacts with the Risperidone in VAL401 to produce 9-hydroxy-Risperidone as expected, demonstrating the suitability of the proposed treatment paradigm, as well as demonstrating that the formulation is compatible with drug absorption and behaviour. Dr Suzy Dilly, CEO of ValiSeek, said: "It is gratifying to be able to share this early trial data release, and in particular to be able to confirm anticipated dosing levels in preparation for the next trial. The analytical databases are now being continuously populated, and I anticipate analysis from this final database to be available, on schedule, before year end." At 8:33am: (LON:VAL) ValiRx PLC share price was +0.03p at 1.05p Story provided by

a d v e r t i s e m e n t